Caribbean International Holdings, Inc. (CIHN) has recently Changed Company Direction to direct its full focus on Regenerative and Personalized Medicine by providing Adult Stem Cell Incubation and Storage for individuals seeking to protect and ensure their quality of life in the future.

There are different kinds of stem cells found in the body that can be utilized for different purposes, however adult stem cells found within a tissue or organ are able to divide itself indefinitely, renew dying cells, and regenerate damaged tissues. As so, adult stem cells have been widely used in human therapies for many years as they are proving to be a solution to over 100 global diseases and conditions.

Through its subsidiary, Regenerative Bio Science, CIHN is utilizing adult stem cells to treat cardiac and vascular patients with health problems including coronary heart disease, peripheral artery disease, congestive heart failure, pulmonary fibrosis, and chronic obstructive pulmonary diseases to limit the number of patients who require bypasses, stents, angiograms, angioplasties and other standard invasive treatments. As heart and lung diseases worsen, these procedures have a limited benefit to the overall health of the patient.

By extracting adult stem cells from a patient’s own blood or bone marrow, said to contain the necessary stem cell to repair and regenerate muscle and form new blood vessels, CIHN is offering patients to improve their quality of life and heal their body in a natural manner. For example, instead of utilizing steroids, neulizer treatments, or bronchodilators to treat the symptoms of pulmonary patients, adult stem cells can repair or replace damaged lung tissue in the bronchioles and alveoli. Likewise, patients with cardiovascular problems could avoid hazardous and unsustainable alternatives such as a pacemaker and defibrillator. Furthermore, the company will extend its patient research to see how stem cells may assist brain injuries including chronic traumatic encephalopathy.

Symbol: CIHN   [ Current PPS: $0.0299   Outstanding Shares: 975M   Float: 33.5M – a/o May 6, 2014 ]

Website(s): www.regenerativebioscience.com

Market

• The Global Stem Cell Market is projected to reach approximately $119.51 billion by 2018 due to global government support for therapeutic research activities for patients with chronic disease and the rising awareness of regenerative treatment options and growing importance of stem cell banking services.
• North America is the current leader in the stem cell market and is expected to maintain its position until 2018
• The Stem Cell Therapy  Market is forecasted to be worth $330 million by 2020.
• Stem Cells hold the solution to approximately 100 global diseases and conditions including diabetes, cancer, Alzheimers, Parkinsons, Lou Gehrig’s Disease (ALS), multiple sclerosis, spinal cord injuries, HIV/AIDs, and blindess.
• Through adult stem cell treatment, research has stated cardiac patients have improved in their 6-minute walking test, increase metabolic equivalent units during stress test, improved and/or increased ejection fraction, and decreased in the Canadian Cardiovascular Society Grading Scale.
• In 2011, eight chronic heart failure patients, in an experimental treatment, with severe heart attack damage and scars were injected with stem cells from their own bone marrow and concluded in healing and shrinking the heart damages by 15%-20%; three times more than current treatments can achieve.
• In 2012, the Science Daily reported a clinical trial conducted by doctors and physicians at the Orland Health Heart Institute concluded stem cells from the pelvic bone may preserve heart function.
• In the U.S., heart disease has become the leading cause of death killing approximately 600,000 people every year.
• Coronary heart disease costs the U.S an annual $109 billion while heart failure costs approximately $32 billion.
• Approximately 720,000 Americans have a heart attack every year while over 5.1 million have heart failure.
• An estimated 50% of people who develop heart failure die within the 5 years of diagnosis.

Recent News

• CIHN has Appointed Rafael Gonzalez, a leader in stem cell research who is currently responsible for the development of clinical stem cell application for numerous diseases and trauma states for a similar company and has extensive knowledge in the execution of all pre-clinical and clinical adult stem cell experiments, to the Advisory Board.
• Dr. Leonel Liriano, another leader in stem cell research who has successfully applied stem cell therapy for over 1,000 people including 200 sports figures, has been appointed as Medical Director.
• The company has begun Processing Initial Requests for its complimentary consultations for patients who will benefit from stem cell procedures.
• New treatment locations have expanded to Guadalajara, Mexico, Cabo St. Lucas, and a pending proprietary lab in the Dominican Republic.

Get Updates on CIHN and other Hot Penny Stocks by Signing Up to our 100% Free Email Newsletter!